MA43181A - Méthodes et compositions comprenant des facteurs de croissances, de la chondroïtine et de la glucosamine pour la régénération d'un disque dégénératif - Google Patents

Méthodes et compositions comprenant des facteurs de croissances, de la chondroïtine et de la glucosamine pour la régénération d'un disque dégénératif

Info

Publication number
MA43181A
MA43181A MA043181A MA43181A MA43181A MA 43181 A MA43181 A MA 43181A MA 043181 A MA043181 A MA 043181A MA 43181 A MA43181 A MA 43181A MA 43181 A MA43181 A MA 43181A
Authority
MA
Morocco
Prior art keywords
chondroitin
glucosamine
regeneration
methods
growth factors
Prior art date
Application number
MA043181A
Other languages
English (en)
Inventor
William Mark Erwin
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MA43181A publication Critical patent/MA43181A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/02Monosaccharides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08Cellulose derivatives
    • C08L1/26Cellulose ethers
    • C08L1/28Alkyl ethers
    • C08L1/286Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA043181A 2015-11-06 2016-11-04 Méthodes et compositions comprenant des facteurs de croissances, de la chondroïtine et de la glucosamine pour la régénération d'un disque dégénératif MA43181A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562252234P 2015-11-06 2015-11-06

Publications (1)

Publication Number Publication Date
MA43181A true MA43181A (fr) 2018-09-12

Family

ID=58661358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043181A MA43181A (fr) 2015-11-06 2016-11-04 Méthodes et compositions comprenant des facteurs de croissances, de la chondroïtine et de la glucosamine pour la régénération d'un disque dégénératif

Country Status (13)

Country Link
US (6) US11141426B2 (fr)
EP (1) EP3370758A4 (fr)
JP (3) JP6989497B2 (fr)
KR (4) KR20240069813A (fr)
CN (2) CN115944712A (fr)
AU (3) AU2016351308C1 (fr)
BR (1) BR112018009214A8 (fr)
CA (1) CA3000757A1 (fr)
MA (1) MA43181A (fr)
MX (2) MX2018005676A (fr)
NZ (2) NZ741320A (fr)
PE (2) PE20181294A1 (fr)
WO (1) WO2017075719A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075719A1 (fr) 2015-11-06 2017-05-11 University Health Network Méthodes et compositions comprenant des facteurs de croissances, de la chondroïtine et de la glucosamine pour la régénération d'un disque dégénératif
CN113820500B (zh) * 2020-06-18 2023-08-11 中国科学院上海有机化学研究所 用于检测退变椎间盘微血管形成的生物标志物及其检测方法
CN112933106A (zh) * 2021-03-17 2021-06-11 上海长征医院 硫酸软骨素在制备预防和治疗椎间盘退变的药物中的应用
US20230158170A1 (en) * 2021-08-24 2023-05-25 Pacira Therapeutics, Inc. IL-1Ra GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION
US11318187B1 (en) 2021-09-02 2022-05-03 Bjorn Eek Treatment of internal disc disruption and connective tissue injuries
US11298406B1 (en) 2021-09-10 2022-04-12 Bjorn Eek Treatment of connective tissue injuries
US12472234B2 (en) * 2021-09-10 2025-11-18 Bjorn Eek Treatment of connective tissue injuries
JP2023129339A (ja) * 2022-03-02 2023-09-14 イーク ビョルン 結合組織損傷の治療

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
US20020026244A1 (en) 2000-08-30 2002-02-28 Trieu Hai H. Intervertebral disc nucleus implants and methods
US20050282774A1 (en) * 2000-10-31 2005-12-22 Eek Bjorn C Method and pharmaceutical to treat spinal discs
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7763077B2 (en) 2003-12-24 2010-07-27 Biomerix Corporation Repair of spinal annular defects and annulo-nucleoplasty regeneration
US20060089719A1 (en) 2004-10-21 2006-04-27 Trieu Hai H In situ formation of intervertebral disc implants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US20070213718A1 (en) * 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Treatment of the vertebral column
US9011930B2 (en) 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
KR20170073614A (ko) 2008-03-21 2017-06-28 티슈진, 인코포레이티드 추간디스크 퇴행 치료용 조성물
US7897164B2 (en) 2008-10-30 2011-03-01 Warsaw Orthopedic, Inc Compositions and methods for nucleus pulposus regeneration
WO2010088775A1 (fr) * 2009-02-06 2010-08-12 University Health Network Procédés et utilisations de cellules de compartiment hypoxique
US8790683B2 (en) * 2009-12-22 2014-07-29 National Cheng Kung University Cell tissue gel containing collagen and hyaluronan
US8398611B2 (en) * 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
ES2604559T3 (es) 2011-04-19 2017-03-07 Bioiberica, S.A. Producto de cartílago
US9649341B2 (en) 2011-04-28 2017-05-16 Warsaw Orthopedic, Inc. Collagen matrix for tissue engineering
US20120294898A1 (en) 2011-05-19 2012-11-22 Warsaw Orthopedic, Inc. Injectable dbm for soft tissue repair
WO2017075719A1 (fr) 2015-11-06 2017-05-11 University Health Network Méthodes et compositions comprenant des facteurs de croissances, de la chondroïtine et de la glucosamine pour la régénération d'un disque dégénératif
US11318187B1 (en) 2021-09-02 2022-05-03 Bjorn Eek Treatment of internal disc disruption and connective tissue injuries
US12472234B2 (en) 2021-09-10 2025-11-18 Bjorn Eek Treatment of connective tissue injuries
US11298406B1 (en) 2021-09-10 2022-04-12 Bjorn Eek Treatment of connective tissue injuries

Also Published As

Publication number Publication date
US20210353664A1 (en) 2021-11-18
JP2022188114A (ja) 2022-12-20
US20260014193A1 (en) 2026-01-15
US12465618B2 (en) 2025-11-11
NZ741320A (en) 2019-12-20
KR20230086817A (ko) 2023-06-15
US11471480B2 (en) 2022-10-18
WO2017075719A1 (fr) 2017-05-11
BR112018009214A8 (pt) 2019-02-26
NZ781522A (en) 2025-06-27
KR20200103891A (ko) 2020-09-02
CA3000757A1 (fr) 2017-05-11
US11141426B2 (en) 2021-10-12
KR20240069813A (ko) 2024-05-20
AU2016351308B2 (en) 2019-10-17
AU2019250267A1 (en) 2019-11-07
BR112018009214A2 (en) 2018-11-06
JP7146840B2 (ja) 2022-10-04
US20190350968A1 (en) 2019-11-21
US20210315922A1 (en) 2021-10-14
KR20180073692A (ko) 2018-07-02
US11141427B2 (en) 2021-10-12
JP2020143106A (ja) 2020-09-10
EP3370758A4 (fr) 2019-06-26
AU2019250267C1 (en) 2022-01-06
MX2024013225A (es) 2024-12-06
US20180169137A1 (en) 2018-06-21
CN108472334A (zh) 2018-08-31
AU2016351308A1 (en) 2018-04-26
AU2021232825A1 (en) 2021-10-14
EP3370758A1 (fr) 2018-09-12
AU2019250267B2 (en) 2021-06-17
US20230121154A1 (en) 2023-04-20
AU2021232825B2 (en) 2025-03-27
JP6989497B2 (ja) 2022-01-05
MX2018005676A (es) 2018-08-01
JP2018537431A (ja) 2018-12-20
PE20181294A1 (es) 2018-08-07
CN115944712A (zh) 2023-04-11
US11491180B2 (en) 2022-11-08
CN108472334B (zh) 2022-12-23
AU2016351308C1 (en) 2022-02-24
AU2019250267B9 (en) 2021-07-08
PE20240683A1 (es) 2024-04-10
NZ759326A (en) 2022-10-28

Similar Documents

Publication Publication Date Title
MA43181A (fr) Méthodes et compositions comprenant des facteurs de croissances, de la chondroïtine et de la glucosamine pour la régénération d'un disque dégénératif
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
IL253727A0 (en) Pure cbd and cbda and methods, preparations and products using cbd or cbda
EP3137605A4 (fr) Compositions et méthodes de modulation de l'expression de l'angiopoïétine de type 3
EP3188782C0 (fr) Système d'humidification contrôlée de façon déterministe
ZA201802451B (en) 2,4-dihydroxy-nicotinamides as apj agonists
EP3121175A4 (fr) Dérivé 1,3-benzodioxole
EP3139966A4 (fr) Méthodes et compositions de traitement de la maladie de huntington
EP3201071A4 (fr) Système de chenille a faibles vibrations
IL257007A (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
EP3137103A4 (fr) Méthodes et compositions pour la modulation du système immunitaire à l'aide de l'arginase i
EP3182979A4 (fr) Nouvelles compositions et méthodes utiles pour traiter ou prévenir des maladies ou des troubles hépatiques et favoriser la perte de poids
EP3235804A4 (fr) Procédé de purification de 1,5-pentanediamine et 1,5-pentanediamine
EP3380603A4 (fr) Procédés, milieux et produits pour la culture d'embryons
EP3354128A4 (fr) Système d'irrigation
EP3356543A4 (fr) Système d'expression de protéines bactériennes modifiées
EP3176149A4 (fr) Procede pour ameliorer la stabilite de conservation de 2,2-difluoroacetaldehyde
EP3334668A4 (fr) Système d'entraînement de convoyeur
EP3212640A4 (fr) Composé ayant une activité agoniste gpr119, procédé pour le préparer, et composition pharmaceutique le comprenant comme constituant efficace
IL251249B (en) Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone
EP3296287A4 (fr) Procédé de purification de 1,4-diaminobutane
EP3383649A4 (fr) Produit d'essuyage absorbant l'huile
FR3035775B1 (fr) Composition attractive pour la bruche de la feverole
EP3127903A4 (fr) Composé de dithiazole 2,2'-tandem, son procédé de préparation et son utilisation
EP3313415A4 (fr) Composition pour la prévention de la croissance microbienne